September 18, 2024Open Access

Outcomes of a patient support programme for subcutaneous immunoglobulin therapy in patients with primary or secondary immunodeficiencies or chronic inflammatory demyelinating polyneuropathy

PCPhilip CrispinAustralian National University RHRobert D. HendersonThe University of Queensland JYJames YunUNSW Sydney

Key Points

Key points are not available for this paper at this time.

Abstract

Subcutaneous immunoglobulin (SCIg) therapy is important in the treatment of primary (PID) and secondary immunodeficiencies (SID) and chronic inflammatory demyelinating polyneuropathy (CIDP). Patient support programmes (PSPs) help patients self-administer medication regimens and play a more active role in the self-management of their medical conditions.

KI fragen

Bookmark

View Full Paper